Covidien says "comfortable" with previously issued guidance Says optimistic about prospects for remainder of year, on track to deliver a solid operational performance this year. For the next few quarters, says expects growth of general surgical to be negatively impacted by the divestiture of the Confluent biosurgery product line. Says growth of Solitaire is accelerating and should perform better this year than previously expected. Currently expects neurovascular growth to pick up throughout 2014. Says looking at "everything" in terms of acquisitions. Comments made on the Q1 earnings conference call.